Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis

Oncogene volume 20, pages 2836–2843 (2001)Cite this article

Abstract

The role of Bcl-2 in TRAIL-induced apoptosis has been investigated in lymphoid cells. Here we show that the human prostatic carcinoma cell line PC3 was sensitive to TRAIL treatment whereas PC3 overexpressing of Bcl-2 was resistant. TRAIL receptors ligation in PC3 activated caspases -2, -3, -7, -8, and -9, induced Bid processing, dissipation of mitochondrial transmembrane potential (ΔΨm), and cytochrome c release. We have detected caspases -8 and -3 only in the cytosolic fraction of cells, but caspases -2, -7, and -9 were found both in cytosolic and mitochondrial fractions. Bcl-2 overexpression did not affect caspase-8 activation although it did change the processing pattern of caspase-3. At the same time, Bcl-2 overexpression inhibited the activation of mitochondrial localized caspases -2, -7, and -9. Bcl-2 also abrogated TRAIL-induced cytochrome c release and dissipation of ΔΨm. These findings suggest that TRAIL-induced apoptosis in the epithelial cell line PC3 depends both on mitochondrial integrity and caspase activation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Baffy G, Miyashita T, Williamson JR, Reed JC . 1993 J. Biol. Chem. 268: 6511–6519

  • Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y . 1999 Int. J. Oncol. 15: 793–802

  • Chandler JM, Cohen GM, MacFarlane M . 1998 J. Biol. Chem. 273: 10815–10818

  • Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM . 1995 Cell 81: 505–512

  • Gewies A, Rokhlin OW, Cohen MB . 2000 Cancer Res. 60: 2163–2168

  • Gotow T, Shibata M, Kanamori S, Tokuno O, Ohsawa Y, Sato N, Isahara K, Yayoi Y, Watanabe T, Leterrier JF, Linden M, Kominami E, Uchiyama Y . 2000 Cell Death Differ. 7: 666–674

  • Green DR, Reed JC . 1998 Science 281: 1309–1312

  • Green DR, Kroemer G . 1998 Trends Cell Biol. 8: 267–271

  • Keogh SA, Walczak H, Bouchier-Hayes L, Martin SJ . 2000 FEBS Lett. 471: 93–98

  • Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A . 2000 Immunity 12: 611–620

  • Li H, Zhu H, Xu CJ, Yuan J . 1998 Cell 94: 491–501

  • Luo X, Budihardjo I, Zou H, Slaughter C, Wang X . 1998 Cell 94: 481–490

  • Mancini M, Machamer CE, Roy S, Nicholson DW, Thornberry NA, Casciola-Rosen LA, Rosen A . 2000 J. Cell Biol. 149: 603–612

  • Mancini M, Nicholson DW, Roy S, Thornberry NA, Peterson EP, Casciola-Rosen LA, Rosen A . 1998 J. Cell Biol. 140: 1485–1495

  • Nicholson DW . 2000 Nature 407: 810–816

  • Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM . 1997a Science 276: 111–113

  • Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM . 1997b Science 266: 815–818

  • Peter M, Kischkel FC, Hellbardt S, Chinnaiyan AM, Krammer PH, Dixit VM . 1996 Cell Death Differ. 3: 161–170

  • Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A . 1996 J. Biol. Chem. 271: 12687–12690

  • Reed JC . 1997 Nature 387: 773–776

  • Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB . 1997 Cancer Res. 57: 1758–1768

  • Rokhlin OW, Glover RA, Cohen MB . 1998 Cancer Res. 58: 5870–5875

  • Rokhlin OW, Gudkov AV, Kwek S, Glover RA, Gewies AS, Cohen MB . 2000 Oncogene 19: 1959–1968

  • Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin K-M, Krammer PH, Peter ME . 1998 EMBO J. 17: 1675–1687

  • Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI . 1997 Curr. Biol. 7: 693–696

  • Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A . 1997 Science 277: 818–821

  • Shimizu S, Eguchi Y, Kamiike W, Waguri S, Uchiyama Y, Matsuda H, Tsujimoto Y . 1996 Oncogene 13: 21–29

  • Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H . 2000 Immunity 12: 599–609

  • Susin SA, Lorenzo HK, Zamzami N, Marzo I, Brenner C, Larochette N, Prevost M-C, Alzari P, Kroemer G . 1999 J. Exp. Med. 189: 381–393

  • Utz PJ, Anderson P . 2000 Cell Death Differ. 7: 589–602

  • Walczak H, Bouchon A, Stahl H, Krammer PH . 2000 Cancer Res. 60: 3051–3057

  • Walczak H, Degli-Esposti WA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA . 2000 EMBO J. 16: 5386–5397

  • Walczak H, Krammer PH . 2000 Exp. Cell Res. 256: 58–66

  • Willey SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA . 1995 Immunity 3: 673–682

  • Yamada H, Tada-Oikawa S, Uchida A, Kawanishi S . 1999 Biochem. Biophys. Res. Commun. 265: 130–133

  • Yang E, Korsmeyer SJ . 1996 Blood 88: 386–401

  • Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X . 1997 Science 275: 1129–1132

  • Zamzami N, Susin SA, Marchetti P, Hirsch T, Gomez-Monterrey I, Castedo M, Kroemer G . 1996 J. Exp. Med. 183: 1533–1544

  • Zhivotovsky B, Samali A, Gahm A, Orrenius S . 1999 Cell Death Differ. 6: 644–651

Download references

Acknowledgements

The authors thank R Glover for technical assistance and A Gewies for assistance with Bcl-2 cDNA recloning. This research was supported by National Institutes of Health grant CA 76673.

Author information

Authors and Affiliations

  1. Department of Pathology, The University of Iowa, Iowa, 52242, IA, USA

    Oskar W Rokhlin, Natalia Guseva, Agshin Tagiyev, C Michael Knudson & Michael B Cohen

  2. Department of Urology, The University of Iowa, Iowa, 52242, IA, USA

    Michael B Cohen

  3. Department of Epidemiology, The University of Iowa, Iowa, 52242, IA, USA

    Michael B Cohen

  4. Veterans Affairs Medical Center, Iowa City, 52242, IA, USA

    Michael B Cohen

Authors
  1. Oskar W Rokhlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natalia Guseva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Agshin Tagiyev
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Michael Knudson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael B Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rokhlin, O., Guseva, N., Tagiyev, A. et al. Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis. Oncogene 20, 2836–2843 (2001). https://doi.org/10.1038/sj.onc.1204410

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204410

Keywords

This article is cited by

Search

Advanced search

Quick links